Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 10/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6504532 | 0.94 | SMN1; SMN2 (0.38) | SMN1; SMN2P2RX7POLB | |
| SCHEMBL6499906 | 0.86 | P2RX7 (0.52) | SMN1; SMN2P2RX7POLBHPGD | |
| SCHEMBL6388648 | 0.81 | P2RX7 (0.50) | SMN1; SMN2P2RX7POLBHPGDL3MBTL1 | |
| SCHEMBL6392653 | 0.80 | SMN1; SMN2 (0.43) | SMN1; SMN2P2RX7POLBHPGDRXFP1 | |
| SCHEMBL6504984 | 0.79 | SMN1; SMN2 (0.44) | SMN1; SMN2P2RX7POLBHPGDRXFP1 | |
| SCHEMBL6388874 | 0.79 | SMN1; SMN2 (0.44) | SMN1; SMN2P2RX7POLBHPGDRXFP1 | |
| SCHEMBL6387573 | 0.79 | SMN1; SMN2 (0.44) | SMN1; SMN2P2RX7POLBHPGDRXFP1 | |
| SCHEMBL6388738 | 0.77 | POLB (0.43) | SMN1; SMN2P2RX7POLBHPGDRXFP1 | |
| SCHEMBL6426530 | 0.77 | P2RX7 (0.35) | P2RX7HPGD | |
| SCHEMBL6390900 | 0.71 | CCNA2 (0.41) | SMN1; SMN2POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | SMN1; SMN2 3733/4885P2RX7 3883/4885POLB 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.